Filtered By:
Drug: Tamoxifen

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 2054 results found since Jan 2013.

Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ER α expression and proliferation in luminal primary and metastatic breast cancer cells
CONCLUSIONS: CHK1 could be considered as an appealing novel pharmacological target for the treatment of luminal primary and MBCs.PMID:35418303 | DOI:10.1186/s13046-022-02360-y
Source: Clinical Breast Cancer - April 14, 2022 Category: Cancer & Oncology Authors: Sara Pescatori Stefano Leone Manuela Cipolletti Stefania Bartoloni Alessandra di Masi Filippo Acconcia Source Type: research

Heat shock protein 90 inhibitor 17-AAG down-regulates thymidine phosphorylase expression and potentiates the cytotoxic effect of tamoxifen and erlotinib in human lung squamous carcinoma cells
Biochem Pharmacol. 2022 Aug 9:115207. doi: 10.1016/j.bcp.2022.115207. Online ahead of print.ABSTRACTElevated thymidine phosphorylase (TP) levels, a key enzyme in the pyrimidine nucleoside salvage pathway, in cancer cells, are related to a poor prognosis in a variety of cancers. Heat shock protein 90 (Hsp90) is a ubiquitous molecular chaperone that is involved in the stabilization and maturation of many oncogenic proteins. The aim of this study is to elucidate whether Hsp90 inhibitor 17-AAG could enhance tamoxifen- and erlotinib-induced cytotoxicity in nonsmall cell lung cancer (NSCLC) cells via modulating TP expression in ...
Source: Biochemical Pharmacology - August 12, 2022 Category: Drugs & Pharmacology Authors: Jen-Chung Ko Jyh-Cheng Chen Jou-Min Hsieh Pei-Yu Tseng Chen-Shan Chiang Li-Ling Liu Chin-Cheng Chien I-Hsiang Huang Qiao-Zhen Chang Bo-Cheng Mu Yun-Wei Lin Source Type: research

Preclinical-to-clinical Anti-cancer Drug Response Prediction and Biomarker Identification Using TINDL
Genomics Proteomics Bioinformatics. 2023 Feb 10:S1672-0229(23)00032-3. doi: 10.1016/j.gpb.2023.01.006. Online ahead of print.ABSTRACTPrediction of the response of cancer patients to different treatments and identification of biomarkers of drug response are two major goals of individualized medicine. Here, we developed a deep learning framework called TINDL, completely trained on preclinical cancer cell lines (CCLs), to predict the response of cancer patients to different treatments. TINDL utilizes a tissue-informed normalization to account for the tissue type and cancer type of the tumors and to reduce the statistical disc...
Source: Genomics Proteomics ... - February 12, 2023 Category: Genetics & Stem Cells Authors: David Earl Hostallero Lixuan Wei Liewei Wang Junmei Cairns Amin Emad Source Type: research

An updated examination of the perception of barriers for pharmacogenomics implementation and the usefulness of drug/gene pairs in Latin America and the Caribbean
In conclusion, although the global contribution of LAC countries remains low in the PGx field, a relevant improvement has been observed in the region. The perception of the usefulness of PGx tests in biomedical community has drastically changed, raising awareness among physicians, which suggests a promising future in the clinical applications of PGx in LAC.PMID:37251329 | PMC:PMC10213898 | DOI:10.3389/fphar.2023.1175737
Source: Cancer Control - May 30, 2023 Category: Cancer & Oncology Authors: Aime é Salas-Hernández Macarena Galleguillos Mat ías Carrasco Andr és López-Cortés Mar ía Ana Redal Dora Fonseca-Mendoza Patricia Esper ón Farith Gonz ález-Martínez Ismael Lares-Asseff Alberto Lazarowski Ver ónica Loera-Castañeda Diadelis Rem Source Type: research

LncRNA AGPG confers endocrine resistance in breast cancer by promoting E2F1 activity
Cancer Res. 2023 Jul 18:CAN-23-0015. doi: 10.1158/0008-5472.CAN-23-0015. Online ahead of print.ABSTRACTResistance to endocrine therapy represents a major concern for patients with estrogen receptor α positive (ERα+) breast cancer. Endocrine therapy resistance is commonly mediated by activated E2F signaling. A better understanding of the mechanisms governing E2F1 activity in resistant cells could reveal strategies for overcoming resistance. Here, we identified the long non-coding RNA (lncRNA) actin gamma 1 pseudogene 25 (AGPG) as a regulator of E2F1 activity in endocrine resistant breast cancer. Expression of EGPG was inc...
Source: Cell Research - July 18, 2023 Category: Cytology Authors: Shiyi Yu Ying Wang Xue Gong Zhehao Fan Zheng Wang Zhengyan Liang Rui Wu Binjie Cao Ning Wang Caili Bi Dan Lv Haibo Sun Source Type: research

Fight Aging! Newsletter, April 18th 2022
In conclusion, our results suggest that SAH extends lifespan by inducing MetR or mimicking its downstream effects. Since the lifespan-extending effects of SAH are conserved in yeast and nematodes, and MetR extends the lifespan of many species, exposure to SAH is expected to have multiple benefits across evolutionary boundaries. Our findings offer the enticing possibility that in humans the benefits of a MetR diet can be achieved by promoting Met reduction with SAH. The use of endogenous metabolites, such as SAH, is considered safer than drugs and other substances, suggesting that it may be one of the most feasible ways to ...
Source: Fight Aging! - April 17, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Free Cancer Research Tool: Use It!
  In preparation for appointments with my doctors, I search Pubmed.gov, a free online database of nearly every medical journal and article in print.  I read articles related to my cancer, print them out, and share them with my docs to review new options for my care or confirm we are on the right track.  As a young adult cancer patient, I have been doing this for nearly a decade. I enter a search term into pubmed.gov. (Here are some general examples of search terms: ‘tamoxifen resistance’ or ‘radioactive iodine uptake’ or ‘testicular protheses’.) Next I click on the title of an art...
Source: Everything Changes - January 15, 2013 Category: Cancer Authors: Kairol Rosenthal Tags: Uncategorized Source Type: blogs

Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
CONCLUSIONS: Primary endocrine therapy should only be offered to women with oestrogen receptor (ER)-positive tumours who are unfit for surgery, at increased risk of serious surgical or anaesthetic complications if subjected to surgery, or who refuse surgery. In a cohort of women with significant co-morbid disease and ER-positive tumours it is possible that primary endocrine therapy may be a superior option to surgery. Trials are needed to evaluate the clinical effectiveness of aromatase inhibitors as primary therapy for an infirm older population with ER-positive tumours. PMID: 24838672 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - May 16, 2014 Category: Journals (General) Authors: Morgan J, Wyld L, Collins KA, Reed MW Tags: Cochrane Database Syst Rev Source Type: research

The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review
Conclusions regarding women with breast cancer who received tamoxifen during COH could not be made due to insufficient data. Peak oestradiol concentrations (338–829 pg/ml) were suppressed by letrozole when commenced on Days 2–3, with no decrease in oocyte yield. Tamoxifen does not supp ress oestradiol concentrations, but may convey protectionvia its inhibitory action on the oestrogen receptor.LIMITATIONS, REASONS FOR CAUTIONAny statements regarding the safety of COH in women with breast cancer are based on a limited number of observational studies. High quality evidence is unlikely to become available for ethical and p...
Source: Human Reproduction - February 27, 2017 Category: Reproduction Medicine Source Type: research

Hypertriglyceridemia-Associated Drug-Induced Acute Pancreatitis
Conclusions Hypertriglyceridemia-associated DIAP is a rare phenomenon, and the current systematic review provides a summary of drugs that have been implicated in this phenomenon, which allow physicians to be oriented about this adverse effect when these drugs are used.
Source: Pancreas - December 14, 2018 Category: Gastroenterology Tags: Reviews Source Type: research

Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence
ConclusionExemestane could be considered as a reasonable therapeutic option in the treatment of ER+ BC at any stage in pre- and postmenopausal women.
Source: Advances in Therapy - January 6, 2022 Category: Drugs & Pharmacology Source Type: research